Compare TTMI & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTMI | PODD |
|---|---|---|
| Founded | 1978 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 10.3B |
| IPO Year | 2000 | 2007 |
| Metric | TTMI | PODD |
|---|---|---|
| Price | $175.42 | $143.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | $127.25 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 2.5M | 1.7M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 211.11 | N/A |
| EPS | 0.47 | ★ 1.30 |
| Revenue | ★ $2,906,345,000.00 | $2,708,100,000.00 |
| Revenue This Year | $18.60 | $24.55 |
| Revenue Next Year | $16.91 | $19.18 |
| P/E Ratio | $401.06 | ★ $109.80 |
| Revenue Growth | 18.98 | ★ 30.73 |
| 52 Week Low | $29.48 | $140.63 |
| 52 Week High | $200.68 | $354.88 |
| Indicator | TTMI | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 29.89 |
| Support Level | $87.36 | N/A |
| Resistance Level | $180.00 | $205.95 |
| Average True Range (ATR) | 12.98 | 5.92 |
| MACD | -0.10 | 0.83 |
| Stochastic Oscillator | 52.47 | 14.12 |
TTM Technologies Inc manufactures technology products, including mission systems, RF components, RF/microwave assemblies, and advanced interconnect products such as PCBs and substrates. It operates through three segments: A&D, Commercial, and RF&S Components. The A&D segment supports aerospace and defense missions with PCBs, assemblies, microelectronics, and integrated systems. The Commercial segment, generating the majority of revenue, serves automotive, medical, industrial, and data center markets. The RF&S Components segment provides TTM-designed RF components and COTS products. The Company's revenues come from PCBs, engineered systems, and long-term contracts for intelligence, surveillance, and communications solutions.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.